20 articles
A new partnership brings standardized spermidine into US clinical settings, shifting longevity science from shelves to physician-guided care.
New research reveals how polyamines flip from supporting healthy aging to turbocharging tumor growth through different cellular pathways.
Declining Menin in the hypothalamus drives inflammation and aging. Restoring it reversed decline; D-serine amino acid improved cognition in mice.
Sironax's SARM1 inhibitor SIR2501 wins FDA Fast Track status for chemotherapy-induced nerve damage, with trials also targeting ALS.
New research frames menopause as a mitochondrial energy crisis, positioning NMN as a targeted NAD⁺ precursor to restore cellular vitality.
Seragon's oral combo therapy SRN-901 outperforms rapamycin in mice, boosting lifespan and slashing frailty through multi-pathway aging intervention.
Dasatinib and quercetin, a leading senolytic combo, unexpectedly reduced myelination in healthy mouse brains, mimicking multiple sclerosis damage.
Johns Hopkins researchers find that a protein producing 'rotten egg' gas in tiny amounts may protect memory and prevent brain damage.
Cognito's Spectris device increased HDL-like lipid transport proteins in cerebrospinal fluid of mild cognitive impairment patients.
Arginine supplements reduced toxic amyloid buildup, brain inflammation, and behavioral decline in fly and mouse Alzheimer's models.
Cognition Therapeutics patents a stable form of CT1812, advancing its Alzheimer's and dementia drug toward registrational trials.
Cognition Therapeutics gets FDA alignment on a registrational study for zervimesine, a promising oral drug for Lewy body dementia with psychosis.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
PulseSight's iron-regulating gene therapy slowed geographic atrophy growth in a first-in-human trial, with Phase 2 planned for 2026.
New research shows combining NMN supplementation with apigenin effectively reverses age-related muscle and bone decline in mice.
A quercetin, NR, urolithin A, and alpha-lipoic acid combination boosted remaining lifespan in aged mice by 33%, even on a Western diet.
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
An oral iron-targeting drug significantly slowed Multiple System Atrophy progression in a Phase 2 trial, with Phase 3 planning underway.
A Harvard small molecule screen identified apigenin as a CD38 inhibitor, revealing how this common flavonoid raises cellular NAD levels.
Definium's single-dose LSD pill cut depression scores by 13 points vs 5 for placebo, with effects holding at 12 weeks.
